Fredsoe et al. validated a blood-based miRNA diagnostic model comprising of 4 miRNAs (miR-375, miR-33a-5p, miR-16-5p and miR-409-3p), called bCaP, in 753 patients with benign prostate lesions and multiple stages of prostate cancer and showed that combined with PSA, digital rectal examination and age bCaP predicted the outcomes of biopsies better than PSA alone [189]. This evidence concerns the gene PROS1 and Familial prostate cancer.